Abstract
Background We previously reported similar efficacies of alveolar ridge preservation (ARP) on single extraction socket with two different E. coli derived recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery systems (Cowell BMP, Cowell medi Co, Busan, Korea; β-tricalcium phosphate and hydroxyapatite particle & O-BMP, Osstem Implant Co, Busan, Korea; absorbable collagen sponge). After the trial, we completed implant therapy and observed over an average of 3 years. This follow-up study was performed retrospectively to compare result of implant treatment at the preserved alveolar ridge site.Methods Patients who underwent extraction of single tooth and received ARP with one of two rhBMP-2 delivery systems from October 2015 to October 2016 were enrolled. Twenty-eight patients (Group 1: Cowell BMP 14; Group 2: O-BMP 14) who underwent implant therapy and prosthetic treatment were included in study. Stability and marginal bone loss (MBL) of each implant were collected from medical charts and radiographs, and analyzed. The survival and success rates of implants were calculated.ResultsThe primary implant stability represented by implant stability quotient (ISQ) for Groups 1 and 2 was 69.71 and 72.86, respectively. The secondary implant stability for Groups 1 and 2 was 78.86 and 81.64, respectively. Primary and secondary stabilities were not statistically different (P = 0.316 and 0.185, respectively). MBL at the latest follow-up was 0.014 mm in Group 1 over 33.76 ± 14.31 months and 0.021 mm in Group 2 over 40.20 ± 9.64 months, with no significant difference (P = 0.670). In addition, the success rate of implants was 100% (14/14) in Group 1 and 92.9% (13/14) in Group 2, with survival rate of 100% (14/14) in Group 1 and 92.9% (13/14) in Group 2.ConclusionsWe confirmed good prognosis in both groups as a result of implant therapy after ARP with each of two rhBMP-2 carriers.
Highlights
We previously reported similar efficacies of alveolar ridge preservation (ARP) on single extraction socket with two different E. coli derived recombinant human bone morphogenetic protein-2 delivery systems (Cowell BMP, Cowell medi Co, Busan, Korea; β-tricalcium phosphate and hydroxyapatite particle & O-BMP, Osstem Implant Co, Busan, Korea; absorbable collagen sponge)
Several studies have shown that bone grafting with recombinant human bone morphogenetic protein-2 (rhBMP-2) at alveolar bone defect sites resulted in clinically and histologically similar volume and quality of alveolar bone compared to outcomes of grafting with autogenous bone [11,12,13]
Since there was no significant difference in groups for marginal bone loss (MBL), success rate, or survival rate, we propose that adequate-quality alveolar bone was formed with implant treatment after ARP with the two rhBMP-2 delivery systems
Summary
We previously reported similar efficacies of alveolar ridge preservation (ARP) on single extraction socket with two different E. coli derived recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery systems (Cowell BMP, Cowell medi Co, Busan, Korea; β-tricalcium phosphate and hydroxyapatite particle & O-BMP, Osstem Implant Co, Busan, Korea; absorbable collagen sponge). We completed implant therapy and observed over an average of 3 years This follow-up study was performed retrospectively to compare result of implant treatment at the preserved alveolar ridge site. The use of autogenous bone for alveolar augmentation and preservation has been considered the gold standard [4]. Complications including donor site comorbidity, limited amount of harvest, resorption after grafting, and difficulty in harvesting because of anatomical and underlying diseases make difficulties to use autogenous bone [3, 4]. Osteoinductive materials have been considered and used for prevention of alveolar bone resorption. Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been authorized to be used for alveolar ridge and maxillary sinus augmentation in the maxillofacial area [10]. It is necessary to identify proper carriers of rhBMP-2 for optimal bone regeneration through osteoinductivity since rhBMP-2 tends to be absorbed when used alone [15,16,17]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
